Glaxosmithkline Pharma Key Ratios
NSE: GLAXO | BSE: 500660
₹2,727.60
As on 20-Nov-2026 15:31IST
Market cap
₹45,841 Cr
Revenue (TTM)
₹4,159 Cr
P/E Ratio
40
P/B Ratio
24.4
Div. Yield
2.1 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 26.12 | 20.78 | 12.12 | 7.92 | 5.45 |
| EBIT | 38.40 | 21.60 | 18.32 | 21.07 | 15.62 |
| Net Profit | 41.61 | 31.42 | 18.87 | 21.22 | 19.49 |
| EPS | 41.61 | 30.44 | 20.03 | 20.97 | 18.24 |
| Book Value | -- | -- | 16.12 | 9.42 | 9.08 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 28.85 | 26.06 | 32.60 | 32.52 | 29.62 |
| Net Margin
| 22.02 | 19.18 | 26.40 | 26.11 | 23.81 |
| Return on equity
| 43.28 | 35.52 | 54.63 | 48.76 | 49.43 |
| Return on Capital
| 59.54 | 51.34 | -- | 66.79 | 67.64 |
| Return on Assets
| 22.56 | 18.86 | 30.04 | 25.40 | 25.15 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
66.79
|
67.64
|
46.49
|
38.06
|
|
Peer Median
|
--
|
20.35
|
21.76
|
21.89
|
--
|
ROE
54.63
Higher than Peers by 40.08
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
54.63
|
48.76
|
49.43
|
33.43
|
27.58
|
|
Peer Median
|
14.55
|
17.72
|
17.93
|
16.42
|
--
|
ROA
30.04
Higher than Peers by 20.55
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
30.04
|
25.40
|
25.15
|
17.87
|
15.76
|
|
Peer Median
|
9.49
|
9.79
|
12.81
|
12.32
|
--
|
EBIT Margin
32.60
Higher than Peers by 15.36
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
32.60
|
32.52
|
29.62
|
24.29
|
22.71
|
|
Peer Median
|
17.24
|
18.34
|
18.93
|
21.05
|
--
|
Net Margin
26.40
Higher than Peers by 13.09
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
26.40
|
26.11
|
23.81
|
16.50
|
18.13
|
|
Peer Median
|
13.31
|
13.29
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
26.11
|
24.12
|
17.43
|
18.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
12.12
Lower than Peers by 0.53
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
12.12
|
1.93
|
8.56
|
6.21
|
-0.80
|
|
Peer Median
|
12.65
|
14.79
|
10.90
|
13.44
|
--
|
EBIT Growth
18.32
Lower than Peers by 3.97
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
18.32
|
11.90
|
32.37
|
13.61
|
6.46
|
|
Peer Median
|
22.30
|
21.09
|
15.01
|
23.50
|
--
|
Net Profit Growth
18.87
Lower than Peers by 3.16
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
18.87
|
11.69
|
57.23
|
-2.91
|
59.58
|
|
Peer Median
|
22.04
|
21.96
|
14.80
|
30.12
|
--
|
EPS Growth
20.03
Higher than Peers by 0.46
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
20.03
|
11.69
|
57.23
|
-3.39
|
-63.97
|
|
Peer Median
|
19.57
|
22.87
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
16.12
|
10.05
|
2.51
|
-34.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.01
|
0.07
|
0.06
|
0.03
|
--
|
Current Ratio
1.79
Lower than Peers by 0.18
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
1.79
|
2.03
|
1.79
|
1.84
|
1.88
|
|
Peer Median
|
1.97
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
1.48
Lower than Peers by 0.01
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
1.48
|
1.77
|
1.54
|
1.49
|
1.53
|
|
Peer Median
|
1.49
|
1.40
|
1.46
|
1.59
|
--
|
Interest Coverage
477.94
Higher than Peers by 458.91
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
477.94
|
515.59
|
960.03
|
454.77
|
462.54
|
|
Peer Median
|
19.03
|
18.94
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
8.16
Lower than Peers by 13.54
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
8.16
|
7.15
|
7.80
|
6.43
|
5.92
|
|
Peer Median
|
21.70
|
20.88
|
21.77
|
20.10
|
--
|
Asset Turnover
1.09
Higher than Peers by 0.38
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
1.09
|
1.04
|
1.12
|
1.15
|
0.93
|
|
Peer Median
|
0.71
|
0.73
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
24.45
|
22.78
|
19.98
|
20.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
40.60
|
44.57
|
47.50
|
50.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
172.70
|
174.99
|
144.03
|
143.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
--
|
-107.65
|
-107.65
|
-76.54
|
-71.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
39.98
Higher than Peers by 6.92
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
39.98
|
37.34
|
52.55
|
55.80
|
36.73
|
|
Peer Median
|
33.06
|
32.71
|
26.81
|
39.85
|
--
|
Price / Book Value
24.37
Higher than Peers by 19.95
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
24.37
|
16.94
|
24.79
|
18.42
|
12.87
|
|
Peer Median
|
4.42
|
4.43
|
4.65
|
6.11
|
--
|
Dividend Yield
2.11
Higher than Peers by 1.73
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
2.11
|
2.50
|
1.88
|
1.65
|
2.42
|
|
Peer Median
|
0.38
|
0.45
|
0.61
|
0.37
|
--
|
EV/EBITDA
28.14
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
28.14
|
25.64
|
35.77
|
30.89
|
23.51
|
|
Peer Median
|
--
|
24.50
|
27.02
|
34.57
|
--
|
Market Cap
45,841
Higher than Peers by 29,990
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
45,841
|
38,682
|
48,743
|
32,917
|
22,432
|
|
Peer Median
|
15,851
|
15,576
|
20,914
|
25,297
|
--
|